接受抗病毒治疗的慢性乙型肝炎肝硬化患者发生肝功能失代偿
该研究为香港和韩国两个前瞻性HBV队列的事后分析,纳入818例基线肝硬度≥10 kPa且代偿期肝病患者,平均随访58.1个月,32例(3.9%)发生肝功能失代偿,其中34%继发于肝细胞癌;符合Baveno VI标准者失代偿发生率高于不符合者(5.9% vs 0.6%,P < .001)。
要点
- 抗病毒治疗下肝硬化患者失代偿并不罕见,仅约三分之一失代偿事件继发于肝细胞癌。
- 基线肝硬度、糖尿病、丙氨酸氨基转移酶、血小板、总胆红素、白蛋白、凝血酶原时间和eGFR是失代偿的独立预测因素。
- Baveno VI标准可用于识别失代偿风险较高的患者。
核心结论
- 接受抗病毒治疗的HBV相关肝硬化患者肝功能失代偿不常见但并未消除,仅约三分之一失代偿事件继发于肝细胞癌。
- 原本用于检测需治疗静脉曲张的Baveno VI标准可有效应用于该人群识别失代偿风险患者。
研究设计与样本
- 香港和韩国两个前瞻性HBV队列的事后分析。
- 纳入基线肝硬度测量≥10 kPa且为代偿期肝病的患者,最终分析818例(平均年龄54.9岁;男性519例[63.4%])。
- 主要终点为发生肝功能失代偿(黄疸或肝硬化并发症),采用竞争风险分析。
主要发现
- 平均随访58.1个月期间,32例(3.9%)患者发生肝功能失代偿,其中34%继发于肝细胞癌。
- 3例(0.4%)仅发生静脉曲张出血,27例(3.3%)发生非出血性失代偿,13例(1.6%)发生超过2次失代偿事件。
- 基线肝硬度、糖尿病、丙氨酸氨基转移酶、血小板、总胆红素、白蛋白、凝血酶原时间和eGFR是肝功能失代偿的独立预测因素。
- 符合Baveno VI标准(肝硬度≥20 kPa和/或血小板计数<150×10⁹/L)的506例患者中30例(5.9%)发生肝功能失代偿,不符合标准的312例患者中2例(0.6%)发生肝功能失代偿(P < .001)。
关键数值与推荐
- Baveno VI标准定义为肝硬度≥20 kPa和/或血小板计数<150×10⁹/L。
- 符合Baveno VI标准者肝功能失代偿发生率为5.9%(30/506),不符合者为0.6%(2/312),差异有统计学意义(P < .001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: It is unclear if anti-hepatitis B virus (HBV) treatment can eliminate incident hepatic decompensation. Here we report the incidence and predictors of hepatic decompensation among cirrhotic patients receiving antiviral therapy for chronic hepatitis B. METHODS: This is a post hoc analysis of two prospective HBV cohorts from Hong Kong and South Korea. Patients with liver stiffness measurement (LSM) ≥10 kPa and compensated liver disease at baseline were included. The primary endpoint was incident hepatic decompensation (jaundice or cirrhotic complications) with competing risk analysis. RESULTS: 818 patients (mean age, 54.9 years; 519 male [63.4%]) were included in the final analysis. During a mean follow-up of 58.1 months, 32 (3.9%) patients developed hepatic decompensation, among whom 34% were secondary to HCC. Three (0.4%) patients experienced variceal bleeding alone, 27 (3.3%) had non-bleeding decompensation and 13 (1.6%) had more than 2 decompensating events Baseline LSM, diabetes, alanine aminotransferase, platelet, total bilirubin, albumin, prothrombin time, and eGFR were independent predictors of hepatic decompensation. 30/506 (5.9%) patients fulfilling the Baveno VI criteria (LSM ≥20 kPa and/or platelet count <150ⅹ109/L) and 2/312 (0.6%) patients not fulfilling the criteria developed hepatic decompensation (P < .001). CONCLUSIONS: Hepatic decompensation is uncommon but not eliminated in patients receiving antiviral therapy for HBV-related cirrhosis, and only a third of decompensating events are secondary to HCC. The Baveno VI criteria, which was originally designed to detect varices needing treatment, can be effectively applied in this population to identify patients at risk of decompensation.
引用
- Lee HW, Yip TC, Tse YK, et al. Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B. Clin Gastroenterol Hepatol. 2020. PMID: 32889148. doi:10.1016/j.cgh.2020.08.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。